News
  Date Title View
Nov 11, 2016
DALLAS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that its lead investigational product candidate Zilretta (also known as FX006) demonstrated clinically and statistically significant improvements in an analysis of Phase 3 trial data conducted in patients with osteoarthritis (OA) o...
Nov 7, 2016
Successfully completed the transfer of the Zilretta™ manufacturing technology to Patheon - on track for NDA submission in December Met primary endpoint in clinical trial evaluating Zilretta in Type 2 diabetes patients with knee osteoarthritis ...
Nov 3, 2016
BURLINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that further analysis of Phase 3 data evaluating its investigational product, Zilretta™ (also known as FX006), in patients with osteoarthritis (OA) of the knee will be presented during the 26th American ...
Nov 1, 2016
-  Results Demonstrate a Markedly Lower Rise in Blood Glucose in Patients Receiving a Zilretta Injection Compared to Patients Receiving an Immediate- Release Triamcinolone Acetonide Injection  --  Difference was Both Statistically Significant and Clinically Relevant  ...
Oct 28, 2016
BURLINGTON, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its third-quarter 2016 financial results on Monday, November 7, 2016, at 4:30 p.m. ET.The dial-in number for the conference call is 855-770-0022 for...
Sep 29, 2016
BURLINGTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- ...
Sep 14, 2016
BURLINGTON, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- ...
Sep 12, 2016
BURLINGTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has made two key appointments to its leadership team: Carolyn Beaty Scimemi, Esq., an experienced compliance and legal professional, as Chief Compliance Officer, and Adam Muzikant, Ph.D., a veteran biotechnol...
Aug 31, 2016
BURLINGTON, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 11th Annual Wells Fargo Securities Healthcare Conference on Wednesday, September 7, 2016 at 2:55 p.m. E...
Aug 3, 2016
Positive data from completed pivotal Phase 2b and Phase 3 registration trials for Zilretta™, Flexion's non-opioid lead drug candidate (also known as FX006), presented at Osteoarthritis Research Society International (OARSI) 2016 World Congress; results demonstrated consistent efficacy across both studies with substan...
FirstPrevious
2
... NextLast
= add release to Briefcase